<?xml version='1.0' encoding='UTF-8'?>
<extracted-tables-set><pmcid/><all-ids><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pmcid">PMC11160843</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pmcid-ver">PMC11160843.1</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pmcaid">11160843</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pmcaiid">11160843</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pmid">38854000</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="doi">10.1101/2024.06.01.24307927</article-id></all-ids><extracted-table><table-id>T1</table-id><table-label>Table 1.</table-label><table-caption>Socio-demographic, symptoms, and imaging measures for the two control groups (orthopedic control, OC, and healthy controls, HC). Values shown are Mean ± SD, with ranges or percentage in ( ). PSQI is the global PSQI score using the Pittsburgh Sleep Quality Questionnaire. RPQ is the total scores from the Rivermead Post Concussion Symptoms questionnaire. Total Number of Symptoms was counted when reported as at least mild symptoms (RPQ ratings ≥ 2). WM-ePVS is the white matter ePVS burden. BG-PVS is the basal ganglia ePVS burden.</table-caption><table-wrap-foot>Significant p-values (p &lt; 0.05) were shown in bold with *.</table-wrap-foot><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" position="float" id="T1" orientation="portrait"><label>Table 1.</label><caption><p id="P52">Socio-demographic, symptoms, and imaging measures for the two control groups (orthopedic control, OC, and healthy controls, HC). Values shown are Mean ± SD, with ranges or percentage in ( ). PSQI is the global PSQI score using the Pittsburgh Sleep Quality Questionnaire. RPQ is the total scores from the Rivermead Post Concussion Symptoms questionnaire. Total Number of Symptoms was counted when reported as at least mild symptoms (RPQ ratings ≥ 2). WM-ePVS is the white matter ePVS burden. BG-PVS is the basal ganglia ePVS burden.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" valign="middle" rowspan="1" colspan="1"/><th align="center" valign="middle" rowspan="1" colspan="1">Orthopedic<break/>Control</th><th align="center" valign="middle" rowspan="1" colspan="1">Healthy<break/>Control</th><th align="center" valign="middle" rowspan="1" colspan="1">p-value<break/>(OC vs. HC)</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">N</td><td align="center" valign="middle" rowspan="1" colspan="1">19</td><td align="center" valign="middle" rowspan="1" colspan="1">18</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Age (yrs)</td><td align="center" valign="middle" rowspan="1" colspan="1">37.3 ± 13.8 (19 – 60)</td><td align="center" valign="middle" rowspan="1" colspan="1">35.5 ± 12.3 (18 – 56)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.79</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Sex (Male)</td><td align="center" valign="middle" rowspan="1" colspan="1">12 (63%)</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (28%)</td><td align="center" valign="middle" rowspan="1" colspan="1"><bold>0.043</bold><xref rid="TFN1" ref-type="table-fn">*</xref></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Education (yrs)</td><td align="center" valign="middle" rowspan="1" colspan="1">13.4 ± 1.9 (11 – 18)</td><td align="center" valign="middle" rowspan="1" colspan="1">17.1 ± 3.4 (10 – 24)</td><td align="center" valign="middle" rowspan="1" colspan="1"><bold>0.0003</bold><xref rid="TFN1" ref-type="table-fn">*</xref></td></tr><tr style="border-bottom: solid 1px"><td align="left" valign="middle" rowspan="1" colspan="1">Days post injury</td><td align="center" valign="middle" rowspan="1" colspan="1">13.8 ± 6.9 (6 – 29)</td><td align="center" valign="middle" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td colspan="4" align="left" valign="middle" rowspan="1"><bold>Symptom Ratings</bold></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PSQI</td><td align="center" valign="middle" rowspan="1" colspan="1">7.4 ± 5.1 (0 – 17)</td><td align="center" valign="middle" rowspan="1" colspan="1">5.2 ± 3.5 (1 – 12)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.17</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">RPQ</td><td align="center" valign="middle" rowspan="1" colspan="1">14.2 ± 15.1 (0 – 48)</td><td align="center" valign="middle" rowspan="1" colspan="1">8.6 ± 7.9 (0 – 26)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.22</td></tr><tr style="border-bottom: solid 1px"><td align="left" valign="middle" rowspan="1" colspan="1">Total Number of Symptoms</td><td align="center" valign="middle" rowspan="1" colspan="1">4.3 ± 4.8 (0 – 14)</td><td align="center" valign="middle" rowspan="1" colspan="1">2.0 ± 2.4 (0 – 8)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.12</td></tr><tr><td colspan="4" align="left" valign="middle" rowspan="1"><bold>Glymphatic Imaging Markers</bold></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">WM-ePVS (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.40 ± 0.18</td><td align="center" valign="middle" rowspan="1" colspan="1">0.39 ± 0.18</td><td align="center" valign="middle" rowspan="1" colspan="1">0.90</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">BG-PVS (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.48 ± 0.21</td><td align="center" valign="middle" rowspan="1" colspan="1">0.59 ± 0.22</td><td align="center" valign="middle" rowspan="1" colspan="1">0.13</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ALPS Index</td><td align="center" valign="middle" rowspan="1" colspan="1">1.49 ± 0.14</td><td align="center" valign="middle" rowspan="1" colspan="1">1.51 ± 0.10</td><td align="center" valign="middle" rowspan="1" colspan="1">0.59</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p id="P53">Significant p-values (p &lt; 0.05) were shown in bold with *.</p></fn></table-wrap-foot></table-wrap></original-table><transformed-table>Table 1.<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Socio-demographic, symptoms, and imaging measures for the two control groups (orthopedic control, OC, and healthy controls, HC). Values shown are Mean ± SD, with ranges or percentage in ( ). PSQI is the global PSQI score using the Pittsburgh Sleep Quality Questionnaire. RPQ is the total scores from the Rivermead Post Concussion Symptoms questionnaire. Total Number of Symptoms was counted when reported as at least mild symptoms (RPQ ratings ≥ 2). WM-ePVS is the white matter ePVS burden. BG-PVS is the basal ganglia ePVS burden.</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><colgroup><col align="left" valign="middle"/><col align="left" valign="middle"/><col align="left" valign="middle"/><col align="left" valign="middle"/></colgroup><thead><tr><th align="left" valign="middle"/><th align="center" valign="middle">OrthopedicControl</th><th align="center" valign="middle">HealthyControl</th><th align="center" valign="middle">p-value(OC vs. HC)</th></tr></thead><tbody><tr><td align="left" valign="middle">N</td><td align="center" valign="middle">19</td><td align="center" valign="middle">18</td><td align="center" valign="middle"/></tr><tr><td align="left" valign="middle">Age (yrs)</td><td align="center" valign="middle">37.3 ± 13.8 (19 – 60)</td><td align="center" valign="middle">35.5 ± 12.3 (18 – 56)</td><td align="center" valign="middle">0.79</td></tr><tr><td align="left" valign="middle">Sex (Male)</td><td align="center" valign="middle">12 (63%)</td><td align="center" valign="middle">5 (28%)</td><td align="center" valign="middle">0.043???</td></tr><tr><td align="left" valign="middle">Education (yrs)</td><td align="center" valign="middle">13.4 ± 1.9 (11 – 18)</td><td align="center" valign="middle">17.1 ± 3.4 (10 – 24)</td><td align="center" valign="middle">0.0003???</td></tr><tr style="border-bottom: solid 1px"><td align="left" valign="middle">Days post injury</td><td align="center" valign="middle">13.8 ± 6.9 (6 – 29)</td><td align="center" valign="middle">N/A</td><td align="center" valign="middle"/></tr><tr><td colspan="4" align="left" valign="middle">Symptom Ratings</td></tr><tr><td align="left" valign="middle">PSQI</td><td align="center" valign="middle">7.4 ± 5.1 (0 – 17)</td><td align="center" valign="middle">5.2 ± 3.5 (1 – 12)</td><td align="center" valign="middle">0.17</td></tr><tr><td align="left" valign="middle">RPQ</td><td align="center" valign="middle">14.2 ± 15.1 (0 – 48)</td><td align="center" valign="middle">8.6 ± 7.9 (0 – 26)</td><td align="center" valign="middle">0.22</td></tr><tr style="border-bottom: solid 1px"><td align="left" valign="middle">Total Number of Symptoms</td><td align="center" valign="middle">4.3 ± 4.8 (0 – 14)</td><td align="center" valign="middle">2.0 ± 2.4 (0 – 8)</td><td align="center" valign="middle">0.12</td></tr><tr><td colspan="4" align="left" valign="middle">Glymphatic Imaging Markers</td></tr><tr><td align="left" valign="middle">WM-ePVS (%)</td><td align="center" valign="middle">0.40 ± 0.18</td><td align="center" valign="middle">0.39 ± 0.18</td><td align="center" valign="middle">0.90</td></tr><tr><td align="left" valign="middle">BG-PVS (%)</td><td align="center" valign="middle">0.48 ± 0.21</td><td align="center" valign="middle">0.59 ± 0.22</td><td align="center" valign="middle">0.13</td></tr><tr><td align="left" valign="middle">ALPS Index</td><td align="center" valign="middle">1.49 ± 0.14</td><td align="center" valign="middle">1.51 ± 0.10</td><td align="center" valign="middle">0.59</td></tr></tbody></table></div>Significant p-values (p &lt; 0.05) were shown in bold with *.</transformed-table></extracted-table><extracted-table><table-id>T2</table-id><table-label>Table 2.</table-label><table-caption>Socio-demographic, symptoms, and imaging measures for control and mTBI patients at two visits (14Day and 6–12Mon). Values shown are Mean ± SD, with ranges or percentage in ( ). Positive CT or MRI findings are based on admission CT and clinical MRI sequences. PSQI is the global PSQI score using the Pittsburgh Sleep Quality Questionnaire. RPQ is the total scores from the Rivermead Post Concussion Symptoms questionnaire. Total Number of Symptoms was counted when reported as at least mild symptoms (RPQ ratings ≥ 2). WM-ePVS is the white matter ePVS burden. BG-PVS is the basal ganglia ePVS burden.</table-caption><table-wrap-foot>Significant p-values (p &lt; 0.05) were shown in bold with *.</table-wrap-foot><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" position="float" id="T2" orientation="portrait"><label>Table 2.</label><caption><p id="P54">Socio-demographic, symptoms, and imaging measures for control and mTBI patients at two visits (14Day and 6–12Mon). Values shown are Mean ± SD, with ranges or percentage in ( ). Positive CT or MRI findings are based on admission CT and clinical MRI sequences. PSQI is the global PSQI score using the Pittsburgh Sleep Quality Questionnaire. RPQ is the total scores from the Rivermead Post Concussion Symptoms questionnaire. Total Number of Symptoms was counted when reported as at least mild symptoms (RPQ ratings ≥ 2). WM-ePVS is the white matter ePVS burden. BG-PVS is the basal ganglia ePVS burden.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" valign="middle" rowspan="1" colspan="1"/><th align="center" valign="middle" rowspan="1" colspan="1">Control</th><th colspan="2" align="center" valign="middle" rowspan="1">mTBI</th><th colspan="2" align="center" valign="middle" rowspan="1">p-value (Control vs. mTBI)</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">N</td><td align="center" valign="middle" rowspan="1" colspan="1">37</td><td colspan="2" align="center" valign="middle" rowspan="1">44</td><td colspan="2" align="center" valign="middle" rowspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Age (yrs)</td><td align="center" valign="middle" rowspan="1" colspan="1">36.7 ± 12.9 (18 – 60)</td><td colspan="2" align="center" valign="middle" rowspan="1">34.5 ± 11.3 (18 – 59)</td><td colspan="2" align="center" valign="middle" rowspan="1">0.41</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Sex (Male)</td><td align="center" valign="middle" rowspan="1" colspan="1">17 (38%)</td><td colspan="2" align="center" valign="middle" rowspan="1">24 (55%)</td><td colspan="2" align="center" valign="middle" rowspan="1">0.51</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Education (yrs)</td><td align="center" valign="middle" rowspan="1" colspan="1">15.2 ± 3.3 (10 – 24)</td><td colspan="2" align="center" valign="middle" rowspan="1">14.2 ± 2.8 (9 – 24)</td><td colspan="2" align="center" valign="middle" rowspan="1">0.17</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Positive CT or MRI</td><td align="center" valign="middle" rowspan="1" colspan="1">N/A</td><td colspan="2" align="center" valign="middle" rowspan="1">20 (45%)</td><td colspan="2" align="center" valign="middle" rowspan="1"/></tr><tr style="border-bottom: solid 1px"><td align="left" valign="middle" rowspan="1" colspan="1">Admission GCS</td><td align="center" valign="middle" rowspan="1" colspan="1">N/A</td><td colspan="2" align="center" valign="middle" rowspan="1">14.7 ± 0.5 (13 – 15)</td><td colspan="2" align="center" valign="middle" rowspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"><bold>14Day</bold></td><td align="center" valign="middle" rowspan="1" colspan="1"><bold>6–12Mon</bold></td><td align="center" valign="middle" rowspan="1" colspan="1"><bold>14Day</bold></td><td align="center" valign="middle" rowspan="1" colspan="1"><bold>6–12Mon</bold></td></tr><tr style="border-bottom: solid 1px"><td align="left" valign="middle" rowspan="1" colspan="1">Days post injury</td><td align="center" valign="middle" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" rowspan="1" colspan="1">13.8 ± 8.1 (2 – 45)</td><td align="center" valign="middle" rowspan="1" colspan="1">306 ± 97 (157 – 508)</td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td colspan="6" align="left" valign="middle" rowspan="1"><bold>Symptom Ratings</bold></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PSQI</td><td align="center" valign="middle" rowspan="1" colspan="1">6.5 ± 4.5 (0 – 17)</td><td align="center" valign="middle" rowspan="1" colspan="1">6.1 ± 3.0 (1 – 14)</td><td align="center" valign="middle" rowspan="1" colspan="1">6.9 ± 3.5 (0 – 14)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.72</td><td align="center" valign="middle" rowspan="1" colspan="1">0.67</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">RPQ</td><td align="center" valign="middle" rowspan="1" colspan="1">11.8 ± 12.6 (0 – 48)</td><td align="center" valign="middle" rowspan="1" colspan="1">21.4 ± 18.4 (0 – 85)</td><td align="center" valign="middle" rowspan="1" colspan="1">21.7 ± 16.5 (0 – 73)</td><td align="center" valign="middle" rowspan="1" colspan="1"><bold>0.014</bold><xref rid="TFN2" ref-type="table-fn">*</xref></td><td align="center" valign="middle" rowspan="1" colspan="1"><bold>0.006</bold><xref rid="TFN2" ref-type="table-fn">*</xref></td></tr><tr style="border-bottom: solid 1px"><td align="left" valign="middle" rowspan="1" colspan="1">Total Number of Symptoms</td><td align="center" valign="middle" rowspan="1" colspan="1">3.3 ± 4.0 (0 – 14)</td><td align="center" valign="middle" rowspan="1" colspan="1">7.1 ± 5.5 (0 – 21)</td><td align="center" valign="middle" rowspan="1" colspan="1">6.8 ± 6.2 (0 – 22)</td><td align="center" valign="middle" rowspan="1" colspan="1"><bold>0.0015</bold><xref rid="TFN2" ref-type="table-fn">*</xref></td><td align="center" valign="middle" rowspan="1" colspan="1"><bold>0.0064</bold><xref rid="TFN2" ref-type="table-fn">*</xref></td></tr><tr><td colspan="6" align="left" valign="middle" rowspan="1"><bold>Glymphatic Imaging Markers</bold></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">WM-ePVS (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.40 ± 0.18</td><td align="center" valign="middle" rowspan="1" colspan="1">0.35 ± 0.26</td><td align="center" valign="middle" rowspan="1" colspan="1">0.38 ± 0.30</td><td align="center" valign="middle" rowspan="1" colspan="1">0.38</td><td align="center" valign="middle" rowspan="1" colspan="1">0.68</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">BG-PVS (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.53 ± 0.22</td><td align="center" valign="middle" rowspan="1" colspan="1">0.50 ± 0.30</td><td align="center" valign="middle" rowspan="1" colspan="1">0.60 ± 0.41</td><td align="center" valign="middle" rowspan="1" colspan="1">0.53</td><td align="center" valign="middle" rowspan="1" colspan="1">0.40</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ALPS Index</td><td align="center" valign="middle" rowspan="1" colspan="1">1.51 ± 0.12</td><td align="center" valign="middle" rowspan="1" colspan="1">1.52 ± 0.13</td><td align="center" valign="middle" rowspan="1" colspan="1">1.50 ± 0.13</td><td align="center" valign="middle" rowspan="1" colspan="1">0.66</td><td align="center" valign="middle" rowspan="1" colspan="1">0.82</td></tr></tbody></table><table-wrap-foot><fn id="TFN2"><p id="P55">Significant p-values (p &lt; 0.05) were shown in bold with *.</p></fn></table-wrap-foot></table-wrap></original-table><transformed-table>Table 2.<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Socio-demographic, symptoms, and imaging measures for control and mTBI patients at two visits (14Day and 6–12Mon). Values shown are Mean ± SD, with ranges or percentage in ( ). Positive CT or MRI findings are based on admission CT and clinical MRI sequences. PSQI is the global PSQI score using the Pittsburgh Sleep Quality Questionnaire. RPQ is the total scores from the Rivermead Post Concussion Symptoms questionnaire. Total Number of Symptoms was counted when reported as at least mild symptoms (RPQ ratings ≥ 2). WM-ePVS is the white matter ePVS burden. BG-PVS is the basal ganglia ePVS burden.</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><colgroup><col align="left" valign="middle"/><col align="left" valign="middle"/><col align="left" valign="middle"/><col align="left" valign="middle"/><col align="left" valign="middle"/><col align="left" valign="middle"/></colgroup><thead><tr><th align="left" valign="middle"/><th align="center" valign="middle">Control</th><th colspan="2" align="center" valign="middle">mTBI</th><th colspan="2" align="center" valign="middle">p-value (Control vs. mTBI)</th></tr></thead><tbody><tr><td align="left" valign="middle">N</td><td align="center" valign="middle">37</td><td colspan="2" align="center" valign="middle">44</td><td colspan="2" align="center" valign="middle"/></tr><tr><td align="left" valign="middle">Age (yrs)</td><td align="center" valign="middle">36.7 ± 12.9 (18 – 60)</td><td colspan="2" align="center" valign="middle">34.5 ± 11.3 (18 – 59)</td><td colspan="2" align="center" valign="middle">0.41</td></tr><tr><td align="left" valign="middle">Sex (Male)</td><td align="center" valign="middle">17 (38%)</td><td colspan="2" align="center" valign="middle">24 (55%)</td><td colspan="2" align="center" valign="middle">0.51</td></tr><tr><td align="left" valign="middle">Education (yrs)</td><td align="center" valign="middle">15.2 ± 3.3 (10 – 24)</td><td colspan="2" align="center" valign="middle">14.2 ± 2.8 (9 – 24)</td><td colspan="2" align="center" valign="middle">0.17</td></tr><tr><td align="left" valign="middle">Positive CT or MRI</td><td align="center" valign="middle">N/A</td><td colspan="2" align="center" valign="middle">20 (45%)</td><td colspan="2" align="center" valign="middle"/></tr><tr style="border-bottom: solid 1px"><td align="left" valign="middle">Admission GCS</td><td align="center" valign="middle">N/A</td><td colspan="2" align="center" valign="middle">14.7 ± 0.5 (13 – 15)</td><td colspan="2" align="center" valign="middle"/></tr><tr><td align="left" valign="middle"/><td align="center" valign="middle"/><td align="center" valign="middle">14Day</td><td align="center" valign="middle">6–12Mon</td><td align="center" valign="middle">14Day</td><td align="center" valign="middle">6–12Mon</td></tr><tr style="border-bottom: solid 1px"><td align="left" valign="middle">Days post injury</td><td align="center" valign="middle">N/A</td><td align="center" valign="middle">13.8 ± 8.1 (2 – 45)</td><td align="center" valign="middle">306 ± 97 (157 – 508)</td><td align="center" valign="middle"/><td align="center" valign="middle"/></tr><tr><td colspan="6" align="left" valign="middle">Symptom Ratings</td></tr><tr><td align="left" valign="middle">PSQI</td><td align="center" valign="middle">6.5 ± 4.5 (0 – 17)</td><td align="center" valign="middle">6.1 ± 3.0 (1 – 14)</td><td align="center" valign="middle">6.9 ± 3.5 (0 – 14)</td><td align="center" valign="middle">0.72</td><td align="center" valign="middle">0.67</td></tr><tr><td align="left" valign="middle">RPQ</td><td align="center" valign="middle">11.8 ± 12.6 (0 – 48)</td><td align="center" valign="middle">21.4 ± 18.4 (0 – 85)</td><td align="center" valign="middle">21.7 ± 16.5 (0 – 73)</td><td align="center" valign="middle">0.014???</td><td align="center" valign="middle">0.006???</td></tr><tr style="border-bottom: solid 1px"><td align="left" valign="middle">Total Number of Symptoms</td><td align="center" valign="middle">3.3 ± 4.0 (0 – 14)</td><td align="center" valign="middle">7.1 ± 5.5 (0 – 21)</td><td align="center" valign="middle">6.8 ± 6.2 (0 – 22)</td><td align="center" valign="middle">0.0015???</td><td align="center" valign="middle">0.0064???</td></tr><tr><td colspan="6" align="left" valign="middle">Glymphatic Imaging Markers</td></tr><tr><td align="left" valign="middle">WM-ePVS (%)</td><td align="center" valign="middle">0.40 ± 0.18</td><td align="center" valign="middle">0.35 ± 0.26</td><td align="center" valign="middle">0.38 ± 0.30</td><td align="center" valign="middle">0.38</td><td align="center" valign="middle">0.68</td></tr><tr><td align="left" valign="middle">BG-PVS (%)</td><td align="center" valign="middle">0.53 ± 0.22</td><td align="center" valign="middle">0.50 ± 0.30</td><td align="center" valign="middle">0.60 ± 0.41</td><td align="center" valign="middle">0.53</td><td align="center" valign="middle">0.40</td></tr><tr><td align="left" valign="middle">ALPS Index</td><td align="center" valign="middle">1.51 ± 0.12</td><td align="center" valign="middle">1.52 ± 0.13</td><td align="center" valign="middle">1.50 ± 0.13</td><td align="center" valign="middle">0.66</td><td align="center" valign="middle">0.82</td></tr></tbody></table></div>Significant p-values (p &lt; 0.05) were shown in bold with *.</transformed-table></extracted-table><extracted-table><table-id>T3</table-id><table-label>Table 3.</table-label><table-caption>Sicio-demographic, symptoms, and imaging measures for mTBI patients with and without memory problems at two visits (14Day and 6–12Mon). The existence of memory problems were defined as RPQ ratings ≥ 2 at the 14Day visit. Values shown are Mean ± SD, with ranges or percentage in ( ). Positive CT or MRI findings are based on admission CT and clinical MRI sequences. PSQI is the global PSQI score using the Pittsburgh Sleep Quality Questionnaire. RPQ is the total scores from the Rivermead Post Concussion Symptoms questionnaire. Total Number of Symptoms was counted when reported as at least mild symptoms (RPQ ratings ≥ 2). WM-ePVS is the white matter ePVS burden. BG-PVS is the basal ganglia ePVS burden. Same mTBI patients were included for both visits, therefore demographic information stays the same.</table-caption><table-wrap-foot>Significant p-values (p &lt; 0.05) were shown in bold with *.</table-wrap-foot><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" position="float" id="T3" orientation="portrait"><label>Table 3.</label><caption><p id="P56">Sicio-demographic, symptoms, and imaging measures for mTBI patients with and without memory problems at two visits (14Day and 6–12Mon). The existence of memory problems were defined as RPQ ratings ≥ 2 at the 14Day visit. Values shown are Mean ± SD, with ranges or percentage in ( ). Positive CT or MRI findings are based on admission CT and clinical MRI sequences. PSQI is the global PSQI score using the Pittsburgh Sleep Quality Questionnaire. RPQ is the total scores from the Rivermead Post Concussion Symptoms questionnaire. Total Number of Symptoms was counted when reported as at least mild symptoms (RPQ ratings ≥ 2). WM-ePVS is the white matter ePVS burden. BG-PVS is the basal ganglia ePVS burden. Same mTBI patients were included for both visits, therefore demographic information stays the same.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" valign="middle" rowspan="1" colspan="1"/><th colspan="2" align="center" valign="middle" rowspan="1">No Memory Prob at 14Day</th><th colspan="2" align="center" valign="middle" rowspan="1">With Memory Prob at 14Day</th><th colspan="2" align="center" valign="middle" rowspan="1">Group Difference (p-value)</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">N</td><td colspan="2" align="center" valign="middle" rowspan="1">21</td><td colspan="2" align="center" valign="middle" rowspan="1">23</td><td colspan="2" align="center" valign="middle" rowspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td colspan="2" align="center" valign="middle" rowspan="1">35.3 ± 11.2 (19 – 59)</td><td colspan="2" align="center" valign="middle" rowspan="1">33.9 ± 11.5 (18 – 53)</td><td colspan="2" align="center" valign="middle" rowspan="1">0.68</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Sex (Male)</td><td colspan="2" align="center" valign="middle" rowspan="1">13 (62%)</td><td colspan="2" align="center" valign="middle" rowspan="1">11 (48%)</td><td colspan="2" align="center" valign="middle" rowspan="1">0.35</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Education (yrs)</td><td colspan="2" align="center" valign="middle" rowspan="1">14.4 ± 3.2 (9 – 24)</td><td colspan="2" align="center" valign="middle" rowspan="1">14.1 ± 2.4 (9 – 18)</td><td colspan="2" align="center" valign="middle" rowspan="1">0.74</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Positive CT or MRI</td><td colspan="2" align="center" valign="middle" rowspan="1">13 (62%)</td><td colspan="2" align="center" valign="middle" rowspan="1">7 (30%)</td><td colspan="2" align="center" valign="middle" rowspan="1">0.067</td></tr><tr style="border-bottom: solid 1px"><td align="left" valign="middle" rowspan="1" colspan="1">Admission GCS</td><td colspan="2" align="center" valign="middle" rowspan="1">14.7 ± 0.7 (13 – 15)</td><td colspan="2" align="center" valign="middle" rowspan="1">14.9 ± 0.4 (14 – 15)</td><td colspan="2" align="center" valign="middle" rowspan="1">0.25</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"><bold>14Day</bold></td><td align="center" valign="middle" rowspan="1" colspan="1"><bold>6–12Mon</bold></td><td align="center" valign="middle" rowspan="1" colspan="1"><bold>14Day</bold></td><td align="center" valign="middle" rowspan="1" colspan="1"><bold>6–12Mon</bold></td><td align="center" valign="middle" rowspan="1" colspan="1"><bold>14Day</bold></td><td align="center" valign="middle" rowspan="1" colspan="1"><bold>6–12Mon</bold></td></tr><tr style="border-bottom: solid 1px"><td align="left" valign="middle" rowspan="1" colspan="1">Days post injury</td><td align="center" valign="middle" rowspan="1" colspan="1">12.8 ± 9.1 (2 – 45)</td><td align="center" valign="middle" rowspan="1" colspan="1">14.6 ± 7.1 (3 – 34)</td><td align="center" valign="middle" rowspan="1" colspan="1">306 ± 99 (157 – 440)</td><td align="center" valign="middle" rowspan="1" colspan="1">305 ± 97 (173 – 508)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.47</td><td align="center" valign="middle" rowspan="1" colspan="1">0.95</td></tr><tr><td colspan="7" align="left" valign="middle" rowspan="1"><bold>Symptom Ratings</bold></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PSQI</td><td align="center" valign="middle" rowspan="1" colspan="1">5.7 ± 3.2 (1 – 14)</td><td align="center" valign="middle" rowspan="1" colspan="1">6.7 ± 4.0 (0 – 14)</td><td align="center" valign="middle" rowspan="1" colspan="1">6.5 ± 2.8 (3 – 13)</td><td align="center" valign="middle" rowspan="1" colspan="1">6.5 ± 2.8 (3 – 14)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.42</td><td align="center" valign="middle" rowspan="1" colspan="1">0.72</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">RPQ</td><td align="center" valign="middle" rowspan="1" colspan="1">7.8 ± 7.1 (0 – 21)</td><td align="center" valign="middle" rowspan="1" colspan="1">15.1 ± 15.6 (0 – 46)</td><td align="center" valign="middle" rowspan="1" colspan="1">33.8 ± 16.7 (15 – 85)</td><td align="center" valign="middle" rowspan="1" colspan="1">27.2 ± 15.4 (4 – 73)</td><td align="center" valign="middle" rowspan="1" colspan="1"><bold>&lt; 0.0001</bold><xref rid="TFN3" ref-type="table-fn">*</xref></td><td align="center" valign="middle" rowspan="1" colspan="1"><bold>0.02</bold><xref rid="TFN3" ref-type="table-fn">*</xref></td></tr><tr style="border-bottom: solid 1px"><td align="left" valign="middle" rowspan="1" colspan="1">Total Number of Symptoms</td><td align="center" valign="middle" rowspan="1" colspan="1">2.7 ± 2.5 (0 – 7)</td><td align="center" valign="middle" rowspan="1" colspan="1">4.0 ± 4.8 (0 – 15)</td><td align="center" valign="middle" rowspan="1" colspan="1">11.0 ± 4.3 (6 – 21)</td><td align="center" valign="middle" rowspan="1" colspan="1">9.3 ± 6.3 (1 – 22)</td><td align="center" valign="middle" rowspan="1" colspan="1"><bold>&lt; 0.0001</bold><xref rid="TFN3" ref-type="table-fn">*</xref></td><td align="center" valign="middle" rowspan="1" colspan="1"><bold>0.004</bold><xref rid="TFN3" ref-type="table-fn">*</xref></td></tr><tr><td colspan="7" align="left" valign="middle" rowspan="1"><bold>Glymphatic Imaging Markers</bold></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">WM-ePVS(%)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.27 ± 0.16</td><td align="center" valign="middle" rowspan="1" colspan="1">0.28 ± 0.17</td><td align="center" valign="middle" rowspan="1" colspan="1">0.44 ± 0.31</td><td align="center" valign="middle" rowspan="1" colspan="1">0.47 ± 0.36</td><td align="center" valign="middle" rowspan="1" colspan="1"><bold>0.016</bold><xref rid="TFN3" ref-type="table-fn">*</xref></td><td align="center" valign="middle" rowspan="1" colspan="1"><bold>0.014</bold><xref rid="TFN3" ref-type="table-fn">*</xref></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">BG-PVS (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.43 ± 0.27</td><td align="center" valign="middle" rowspan="1" colspan="1">0.53 ± 0.32</td><td align="center" valign="middle" rowspan="1" colspan="1">0.56 ± 0.32</td><td align="center" valign="middle" rowspan="1" colspan="1">0.76 ± 0.64</td><td align="center" valign="middle" rowspan="1" colspan="1">0.17</td><td align="center" valign="middle" rowspan="1" colspan="1">0.14</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ALPS Index</td><td align="center" valign="middle" rowspan="1" colspan="1">1.53 ± 0.13</td><td align="center" valign="middle" rowspan="1" colspan="1">1.49 ± 0.14</td><td align="center" valign="middle" rowspan="1" colspan="1">1.50 ± 0.13</td><td align="center" valign="middle" rowspan="1" colspan="1">1.50 ± 0.12</td><td align="center" valign="middle" rowspan="1" colspan="1">0.44</td><td align="center" valign="middle" rowspan="1" colspan="1">0.82</td></tr></tbody></table><table-wrap-foot><fn id="TFN3"><p id="P57">Significant p-values (p &lt; 0.05) were shown in bold with *.</p></fn></table-wrap-foot></table-wrap></original-table><transformed-table>Table 3.<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Sicio-demographic, symptoms, and imaging measures for mTBI patients with and without memory problems at two visits (14Day and 6–12Mon). The existence of memory problems were defined as RPQ ratings ≥ 2 at the 14Day visit. Values shown are Mean ± SD, with ranges or percentage in ( ). Positive CT or MRI findings are based on admission CT and clinical MRI sequences. PSQI is the global PSQI score using the Pittsburgh Sleep Quality Questionnaire. RPQ is the total scores from the Rivermead Post Concussion Symptoms questionnaire. Total Number of Symptoms was counted when reported as at least mild symptoms (RPQ ratings ≥ 2). WM-ePVS is the white matter ePVS burden. BG-PVS is the basal ganglia ePVS burden. Same mTBI patients were included for both visits, therefore demographic information stays the same.</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><colgroup><col align="left" valign="middle"/><col align="left" valign="middle"/><col align="left" valign="middle"/><col align="left" valign="middle"/><col align="left" valign="middle"/><col align="left" valign="middle"/><col align="left" valign="middle"/></colgroup><thead><tr><th align="left" valign="middle"/><th colspan="2" align="center" valign="middle">No Memory Prob at 14Day</th><th colspan="2" align="center" valign="middle">With Memory Prob at 14Day</th><th colspan="2" align="center" valign="middle">Group Difference (p-value)</th></tr></thead><tbody><tr><td align="left" valign="middle">N</td><td colspan="2" align="center" valign="middle">21</td><td colspan="2" align="center" valign="middle">23</td><td colspan="2" align="center" valign="middle"/></tr><tr><td align="left" valign="middle"/><td colspan="2" align="center" valign="middle">35.3 ± 11.2 (19 – 59)</td><td colspan="2" align="center" valign="middle">33.9 ± 11.5 (18 – 53)</td><td colspan="2" align="center" valign="middle">0.68</td></tr><tr><td align="left" valign="middle">Sex (Male)</td><td colspan="2" align="center" valign="middle">13 (62%)</td><td colspan="2" align="center" valign="middle">11 (48%)</td><td colspan="2" align="center" valign="middle">0.35</td></tr><tr><td align="left" valign="middle">Education (yrs)</td><td colspan="2" align="center" valign="middle">14.4 ± 3.2 (9 – 24)</td><td colspan="2" align="center" valign="middle">14.1 ± 2.4 (9 – 18)</td><td colspan="2" align="center" valign="middle">0.74</td></tr><tr><td align="left" valign="middle">Positive CT or MRI</td><td colspan="2" align="center" valign="middle">13 (62%)</td><td colspan="2" align="center" valign="middle">7 (30%)</td><td colspan="2" align="center" valign="middle">0.067</td></tr><tr style="border-bottom: solid 1px"><td align="left" valign="middle">Admission GCS</td><td colspan="2" align="center" valign="middle">14.7 ± 0.7 (13 – 15)</td><td colspan="2" align="center" valign="middle">14.9 ± 0.4 (14 – 15)</td><td colspan="2" align="center" valign="middle">0.25</td></tr><tr><td align="left" valign="middle"/><td align="center" valign="middle">14Day</td><td align="center" valign="middle">6–12Mon</td><td align="center" valign="middle">14Day</td><td align="center" valign="middle">6–12Mon</td><td align="center" valign="middle">14Day</td><td align="center" valign="middle">6–12Mon</td></tr><tr style="border-bottom: solid 1px"><td align="left" valign="middle">Days post injury</td><td align="center" valign="middle">12.8 ± 9.1 (2 – 45)</td><td align="center" valign="middle">14.6 ± 7.1 (3 – 34)</td><td align="center" valign="middle">306 ± 99 (157 – 440)</td><td align="center" valign="middle">305 ± 97 (173 – 508)</td><td align="center" valign="middle">0.47</td><td align="center" valign="middle">0.95</td></tr><tr><td colspan="7" align="left" valign="middle">Symptom Ratings</td></tr><tr><td align="left" valign="middle">PSQI</td><td align="center" valign="middle">5.7 ± 3.2 (1 – 14)</td><td align="center" valign="middle">6.7 ± 4.0 (0 – 14)</td><td align="center" valign="middle">6.5 ± 2.8 (3 – 13)</td><td align="center" valign="middle">6.5 ± 2.8 (3 – 14)</td><td align="center" valign="middle">0.42</td><td align="center" valign="middle">0.72</td></tr><tr><td align="left" valign="middle">RPQ</td><td align="center" valign="middle">7.8 ± 7.1 (0 – 21)</td><td align="center" valign="middle">15.1 ± 15.6 (0 – 46)</td><td align="center" valign="middle">33.8 ± 16.7 (15 – 85)</td><td align="center" valign="middle">27.2 ± 15.4 (4 – 73)</td><td align="center" valign="middle">&lt; 0.0001???</td><td align="center" valign="middle">0.02???</td></tr><tr style="border-bottom: solid 1px"><td align="left" valign="middle">Total Number of Symptoms</td><td align="center" valign="middle">2.7 ± 2.5 (0 – 7)</td><td align="center" valign="middle">4.0 ± 4.8 (0 – 15)</td><td align="center" valign="middle">11.0 ± 4.3 (6 – 21)</td><td align="center" valign="middle">9.3 ± 6.3 (1 – 22)</td><td align="center" valign="middle">&lt; 0.0001???</td><td align="center" valign="middle">0.004???</td></tr><tr><td colspan="7" align="left" valign="middle">Glymphatic Imaging Markers</td></tr><tr><td align="left" valign="middle">WM-ePVS(%)</td><td align="center" valign="middle">0.27 ± 0.16</td><td align="center" valign="middle">0.28 ± 0.17</td><td align="center" valign="middle">0.44 ± 0.31</td><td align="center" valign="middle">0.47 ± 0.36</td><td align="center" valign="middle">0.016???</td><td align="center" valign="middle">0.014???</td></tr><tr><td align="left" valign="middle">BG-PVS (%)</td><td align="center" valign="middle">0.43 ± 0.27</td><td align="center" valign="middle">0.53 ± 0.32</td><td align="center" valign="middle">0.56 ± 0.32</td><td align="center" valign="middle">0.76 ± 0.64</td><td align="center" valign="middle">0.17</td><td align="center" valign="middle">0.14</td></tr><tr><td align="left" valign="middle">ALPS Index</td><td align="center" valign="middle">1.53 ± 0.13</td><td align="center" valign="middle">1.49 ± 0.14</td><td align="center" valign="middle">1.50 ± 0.13</td><td align="center" valign="middle">1.50 ± 0.12</td><td align="center" valign="middle">0.44</td><td align="center" valign="middle">0.82</td></tr></tbody></table></div>Significant p-values (p &lt; 0.05) were shown in bold with *.</transformed-table></extracted-table><extracted-table><table-id>T4</table-id><table-label>Table 4.</table-label><table-caption>Logistic regression model coefficients for Model 2 (Figure 7). Among all socio-demographic and clinical information, Education and CT or MRI findings were selected to compose the best logistic model for prediction of 6–12Mon memory problem.</table-caption><table-wrap-foot>14Day WM-ePVS and ALPS were also significant factors (bolded with *).</table-wrap-foot><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" position="float" id="T4" orientation="portrait"><label>Table 4.</label><caption><p id="P58">Logistic regression model coefficients for Model 2 (<xref rid="F7" ref-type="fig">Figure 7</xref>). Among all socio-demographic and clinical information, Education and CT or MRI findings were selected to compose the best logistic model for prediction of 6–12Mon memory problem.</p></caption><table frame="box" rules="all"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Coefficients</th><th align="center" valign="top" rowspan="1" colspan="1">Estimate Std.</th><th align="center" valign="top" rowspan="1" colspan="1">Error</th><th align="center" valign="top" rowspan="1" colspan="1">Z value</th><th align="center" valign="top" rowspan="1" colspan="1">Pr(&gt;|z|)</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">(Intercept)</td><td align="center" valign="top" rowspan="1" colspan="1">−10.4160</td><td align="center" valign="top" rowspan="1" colspan="1">5.3262</td><td align="center" valign="top" rowspan="1" colspan="1">−1.956</td><td align="center" valign="top" rowspan="1" colspan="1">0.0505</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Education</td><td align="center" valign="top" rowspan="1" colspan="1">−0.2367</td><td align="center" valign="top" rowspan="1" colspan="1">0.1184</td><td align="center" valign="top" rowspan="1" colspan="1">−1.999</td><td align="center" valign="top" rowspan="1" colspan="1">0.0456</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CT_or_MRI (Yes)</td><td align="center" valign="top" rowspan="1" colspan="1">−1.6464</td><td align="center" valign="top" rowspan="1" colspan="1">0.8532</td><td align="center" valign="top" rowspan="1" colspan="1">−1.930</td><td align="center" valign="top" rowspan="1" colspan="1">0.0536</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">WM-ePVS</td><td align="center" valign="top" rowspan="1" colspan="1">3.5513</td><td align="center" valign="top" rowspan="1" colspan="1">1.7045</td><td align="center" valign="top" rowspan="1" colspan="1">2.084</td><td align="center" valign="top" rowspan="1" colspan="1"><bold>0.0372</bold><xref rid="TFN4" ref-type="table-fn">*</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">APLS</td><td align="center" valign="top" rowspan="1" colspan="1">9.3073</td><td align="center" valign="top" rowspan="1" colspan="1">3.8718</td><td align="center" valign="top" rowspan="1" colspan="1">2.404</td><td align="center" valign="top" rowspan="1" colspan="1"><bold>0.0162</bold><xref rid="TFN4" ref-type="table-fn">*</xref></td></tr></tbody></table><table-wrap-foot><fn id="TFN4"><p id="P59">14Day WM-ePVS and ALPS were also significant factors (bolded with *).</p></fn></table-wrap-foot></table-wrap></original-table><transformed-table>Table 4.<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Logistic regression model coefficients for Model 2 (???). Among all socio-demographic and clinical information, Education and CT or MRI findings were selected to compose the best logistic model for prediction of 6–12Mon memory problem.</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="box" rules="all"><colgroup><col align="left" valign="middle"/><col align="left" valign="middle"/><col align="left" valign="middle"/><col align="left" valign="middle"/><col align="left" valign="middle"/></colgroup><thead><tr><th align="left" valign="top">Coefficients</th><th align="center" valign="top">Estimate Std.</th><th align="center" valign="top">Error</th><th align="center" valign="top">Z value</th><th align="center" valign="top">Pr(&gt;|z|)</th></tr></thead><tbody><tr><td align="left" valign="top">(Intercept)</td><td align="center" valign="top">−10.4160</td><td align="center" valign="top">5.3262</td><td align="center" valign="top">−1.956</td><td align="center" valign="top">0.0505</td></tr><tr><td align="left" valign="top">Education</td><td align="center" valign="top">−0.2367</td><td align="center" valign="top">0.1184</td><td align="center" valign="top">−1.999</td><td align="center" valign="top">0.0456</td></tr><tr><td align="left" valign="top">CT_or_MRI (Yes)</td><td align="center" valign="top">−1.6464</td><td align="center" valign="top">0.8532</td><td align="center" valign="top">−1.930</td><td align="center" valign="top">0.0536</td></tr><tr><td align="left" valign="top">WM-ePVS</td><td align="center" valign="top">3.5513</td><td align="center" valign="top">1.7045</td><td align="center" valign="top">2.084</td><td align="center" valign="top">0.0372???</td></tr><tr><td align="left" valign="top">APLS</td><td align="center" valign="top">9.3073</td><td align="center" valign="top">3.8718</td><td align="center" valign="top">2.404</td><td align="center" valign="top">0.0162???</td></tr></tbody></table></div>14Day WM-ePVS and ALPS were also significant factors (bolded with *).</transformed-table></extracted-table></extracted-tables-set>